Consistently, over and over again, the biggest question at this point is funding level, not science. If that can be addressed from Al Mann or from a partnership, I think we will see a significant spike upwards. I am not expecting too much because I still think that the market sees the inhaled insulin (Exubera) risk of viability and marketability to consumers, which of course I don't agree with! I think that funding committment from Mann presents a nice spike, but not nearly to the extent that a partnership from BP would represent.